Prevail therapeutics inc. (PRVL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities
Net loss

-18,575

-17,841

-20,299

-15,103

-9,945

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

111

64

108

56

37

Stock-based compensation

1,632

1,294

1,296

1,109

612

Changes in operating assets and liabilities
Prepaid expenses and other current assets

-1,501

-1,015

3,172

-130

3,820

Other long-term assets

1,817

-

-

-

-

Operating lease right-of-use asset

319

311

308

701

317

Accounts payable

-1,219

210

2,949

50

712

Accrued expenses and other current liabilities

122

241

534

3,146

-68

Operating lease liabilities

-320

-93

-225

-218

-170

Net cash used in operating activities

-18,246

-14,799

-18,501

-10,129

-12,325

Cash flows from investing activities
Purchases of property and equipment

287

86

512

1,282

256

Net cash used in investing activities

-287

-86

-512

-1,282

-256

Cash flows from financing activities
Payment of issuance costs for preferred stock

-

0

0

0

166

Proceeds from exercise of stock options

62

-

-

-

-

Net cash provided by financing activities

62

-138

-8

113,239

49,834

Net increase (decrease) in cash, cash equivalents and restricted cash

-18,471

-

-

-

37,253

Series B Preferred Stock
Proceeds from issuance of Series B Preferred Stock

-

0

0

0

50,000